Outlook Therapeutics, Inc.
Financial highlights
| Metric | FY 09/30/25 | FY 09/30/24 | FY 09/30/23 | FY 09/30/22 | FY 09/30/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.4 | — | — | — | — |
| Operating income | -$67.1 | -$71.7 | -$53.1 | -$63.1 | -$51.7 |
| Net income | -$62.4 | -$75.4 | -$59.0 | -$66.1 | -$53.2 |
| Balance Sheet | |||||
| Total debt | — | — | $35.6 | $11.1 | $11.8 |
| Cash Flow Statement | |||||
| Dividends | — | $0.0 | $0.0 | — | — |
Shares outstanding 120.9M · Free float 45.7%
Annual filing data through FY ended September 30, 2025; float as of July 14, 2026.